- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. TORII PHARMACEUTICAL CO., LTD. is mainly engaged in the manufacture and sale of pharmaceutical products. In addition to Torii’s independent activities, Torii‘s partnership with JT includes in-licensing of high-quality pharmaceuticals. Latest News; Careers; - Assess the growth potential of Torii Pharmaceutical Co., Ltd. in its therapy areas of focus. January 15, 2020. Torii Pharmaceutical will pay tiered royalties of up to 40 percent of Japanese net sales of berotralstat to BioCryst upon receipt of a reimbursement price approval NHI Japan. The corporate mission of Torii Pharmaceutical Co., Ltd. is to contribute to the improvement of human health and to fulfill its responsibilities to customers, shareholders, society and employees, by supplying world-class pharmaceutical products. August 05, 2020. Pharmaceutical Pipeline . Upfront Cash: Undisclosed, Deal Type: Licensing Agreement - Exploit collaboration and partnership opportunities with Torii Pharmaceutical Co., Ltd.. - Avoid Intellectual Property Rights related issues. Torii Pharmaceutical operates building maintenance and management business as well as shipping business. The agreement grants Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102. Serlopitant is a first–in-class, once-daily oral NK-1 receptor … Review the pipeline and the status of clinical studies investigating APL-2 (pegcetacoplan) & APL-9 as a treatment for autoimmune and inflammatory diseases, including geographic atrophy (GA), paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin disease (CAD), warm antibody autoimmune hemolytic anemia (wAIHA), and complement dependent nephropathies (CDN) - Identify new drug targets and therapeutic classes in the Torii Pharmaceutical Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. Torii Pharmaceutical Co., Ltd. (4551) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. Cantharidin, Therapeutic Area: Infections and Infectious Diseases With its corporate mission" Torii Pharmaceutical Co., Ltd. aims to contribute to the improvement of human health and to fulfill its responsibilities to customers, shareholders, society and employees, by supplying world-class pharmaceutical products. Product Type: Small molecule, Recipient: The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. See the company profile for TORII PHARMACEUTICAL CO (4551.T) including business summary, industry/sector information, number of employees, business … Reportstack has announced a new market research publication on Torii Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013 which provides data on the Torii Pharmaceutical Co., Ltd.’s research and development focus. This page provides a list of Taiho products currently under development (showing pipeline progress). Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan Email Print Friendly Share August 05, 2020 07:00 ET | … Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan PRESS RELEASE GlobeNewswire Aug. 5, 2020, 07:00 AM Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Torii Pharmaceutical Late Stage Pipeline. - Recent updates of the Torii Pharmaceutical Co., Ltd.’s pipeline in the last quarter. Deal leverages Torii’s proven track record to deliver innovative therapies to Japanese patients— RESEARCH TRIANGLE PARK, NC, USA I November 05, 2019 I BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced that it has licensed commercialization rights in Japan to Torii Pharmaceutical, Co. for BCX7353, an oral, once-daily treatment for the prevention of hereditary … 4551:JP 2,893.00 JPY +42.00 +1.47%. This is the homepage of Torii Pharmaceutical Co., Ltd. We aim to contribute to the improvement of people's health by supplying world-class pharmaceutical products. Product Name: VP-102, Highest Development Status: Phase III This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies. Pipeline. Under the terms of the agreementwith Dermavant, JT will be responsible for the development and commercialization of tapinarof in Japan. Dermatomyositis. October 13, 2020. × Price for Single User $ 250 USD :: SummaryTorii Pharmaceutical Co., Ltd. (Torii) a subsidiary of Japan Tobacco Inc. is a pharmaceutical company that manufactures and markets products such as antebate ointment, antebate cream and urinorm used for the treatment of hyperuricemia and gout By continuing to browse this site, you agree to the use of cookies. 015 Corporate Report 2019 ONO PHARMACEUTICAL CO., LTD. Systemic Sclerosis. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Systemic sclerosis (SSc), a form of scleroderma, is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S., EU and Japan. with Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551), a subsidiary of JT, for co-development and commercialization of tapinarof in Japan. Reportstack has announced a new market research publication on Torii Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013 which provides data on the Torii Pharmaceutical Co., Ltd.’s research and development focus. 2020/11/13 FY2020(2nd quarter) Supplementary Material of Financial Results Download PDF. Delgocitinib, Therapeutic Area: Dermatology Ratios valuation of Torii Pharmaceutical Co., Ltd. ( 4551 | JPN) The EV/EBITDA NTM ratio (also called EBITDA multiple or enterprise multiple) is a well-known company valuation metric that compares a company's overall value to its operational earning power. This site uses cookies to improve your experience on the site. Lead Product(s): Scope- Torii Pharmaceutical Co., Ltd. - Brief Torii Pharmaceutical Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.- Review of current pipeline of Torii Pharmaceutical Co., Ltd. human therapeutic division.- Overview of pipeline therapeutics across various therapy areas.- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.- Product profiles for late stage and clinical stage products of Torii Pharmaceutical Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. To view the table of contents and know more details please visit Torii Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013. Chromatography (TLC / LC / HPLC / UPLC / GC), Complete Pharmacopoeial / Compendial Testing, Bioanalytical & Biomarker Testing Services, Bioequivalence / Clinical / Pre-Clinical Testing, Calculation and Modeling of Pharmacokinetic Parameters, Protein isolation, identification and characterization, Electrical Conductivity / High Voltage Leak Detection (HVLD), Mass Flow / Mass Extraction Leak Detection, European and Japanese Pharmacopoeia (EP & JP) Container Testing, ASTM and ISTA Distribution Simulation Testing, Environmental Conditioning, Cycling and Simulation Testing, Controlled / Immediate / Modified Release, Health / Dietary Supplement (Nutraceutical), Low Temperature / Cryogenic Condition (-78 °C), Pharmacokinetics / Pharmacodynamics / Pharmacometrics, Clinical Research Translation / Validation, Pharmacovigilance / Product Lifecycle Management, High Potent / Biologic / Controlled Substance, Customization (Anodizing, Siliconization, Plastic Coating), Media / Public Relations / Communications, Methacrylic Acid - Ethyl Acrylate Copolymer, Methacrylic Acid Methyl Methacrylate Copolymer, Polyvinyl Alcohol Graft Polyethylene Glycol Copolymer, Betadex Sulfobutyl Ether Sodium Excipient, Hydroxypropyl methylcellulose acetate succinate, Cross Linked Sodium Carboxymethylcellulose, Hepatology (Liver, Pancreatic, Gall Bladder), Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan, BioCryst Submits Japanese NDA for Oral, Once Daily Berotralstat, JT to market CORECTIM in Japan to treat atopic dermatitis. ¿Qué herramientas de análisis técnico se pueden usar para analizar TORII PHARMACEUTICAL CO? We incorporated Torii Pharmaceutical as a Group company in 1998 to strengthen our domestic pharmaceutical business. Torii Pharma focuses on Renal diseases, Hemodialysis, Allergy and Skin diseases as its therapeutic areas of importance. 1 SSc is more common in adults and women than in men and children, and typically occurs in people aged 30 to 50 years old. In light of our corporate philosophy, "We strive to improve human health and contribute to a society enriched by smiles," we aim to become a company that can contribute to people all over the world. Proposed Indication Development Stage Area I II III Filed ONO-7643 Torii Pharmaceutical raises consolidated full-year outlook for FY 2015. Upfront Cash: $22.0 million, Deal Type: Agreement In light of our corporate philosophy, "We strive to improve human health and contribute to a society enriched by smiles," we aim to become a company that can contribute to people all over the world. We have established a diversified product pipeline with numerous late-stage development assets across a variety of dosage forms. Torii Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemi a improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable … Description. Kalorama Information’s Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. - Key discontinued and dormant projects. Quick Links. The Company’s robust medical dermatology pipeline includes both late-stage and early-development product candidates that target specific unmet needs in two of the - Latest news and deals relating to the products.Reasons to buy- Evaluate Torii Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline. Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE, Lead Product(s): As … This page provides a list of Taiho products currently under development (showing pipeline progress). Vea diversos osciladores, medias móviles y otros indicadores técnicos en TradingView. Berotralstat, Therapeutic Area: Genetic Disease Tourette Syndrome - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Tourette Syndrome (Central Nervous System), complete with … Masanori Wada is Former Director at Torii Pharmaceutical Co Ltd. See Masanori Wada's compensation, career history, education, & memberships. El organigrama de Torii Pharmaceutical muestra a sus 12 principales ejecutivos de los cuales Shoichiro Takagi y Akihiko Tamura Towa Pharmaceutical Co., Ltd. | Medicine meeting your needs. Eton Pharmaceuticals is focused on bringing innovative, high-value 505(b)(2) products to patients. About Torii Pharmaceutical Co., Ltd. Furthermore, this agreement grants JT prioritized CURRENT PRICE. Upfront Cash: $11.5 million, Deal Type: Agreement Japan Tobacco, Deal Size: Undisclosed Torii is a member of Japan Tobacco Inc. (JT) group. Teva’s Global R&D organization helps propel the company’s mission to be a global leader in generics and biopharmaceuticals. Product Name: Undisclosed, Partner/Sponsor/Collaborator: The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. About Torii Pharmaceutical Co., Ltd. With its corporate mission“ Torii Pharmaceutical Co., Ltd. aims to contribute to the improvement of human health and to fulfill its responsibilities to customers, shareholders, society and employees, by supplying world-class pharmaceutical products. Teva Specialty Product Pipeline by development stage - November 2020. Accept. Key 2020 Events . Consulta las últimas cotizaciones de acciones, historial, noticias y otra información vital de TORII PHARMACEUTICAL CO (4551.T) para ayudarte con tus operaciones bursátiles e inversiones. Torii is a member of Japan Tobacco Inc. (JT) group. Collaboration with JT takes the form of functional focus, with JT undertaking R&D on new compounds and Torii integrating manufacture and marketing. To maximize synergies, JT now concentrates on R&D activities while Torii Pharmaceutical is in charge of manufacturing, sales and promotion. Unlike most other triple combinations, which are chosen in part from the pharmaceutical company’s list of existing products, our triple combination drug contains what we consider to be the best-in-class drug in each category. BioCryst Pharmaceuticals, Deal Size: $42.0 million Verrica Pharmaceuticals, Deal Size: $70.0 million NEW YORK, NY, USA I April 23, 2012 I Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), announced today that its Japanese partner, Japan Tobacco Inc. (JT) and Torii Pharmaceutical Co., Ltd. (Torii), has announced positive top-line results from a Phase 3 study of ferric citrate in Japan for the treatment of hyperphosphatemia in end-stage renal disease patients on hemodialysis. Product Name: Undisclosed, Recipient: October 13, 2020. They have been compiled below into an infographic of Torii's Japan sales performance . Lead Product(s): Our Intended Regulatory Pathway . Torii Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack.This report provides an overview of the Torii Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus. MENLO PARK, CA, USA I August 10, 2016 I Menlo Therapeutics Inc., (Menlo Park, CA) announced today that it has entered into an exclusive license agreement with Japan Tobacco Inc. (JT) (TSE:2914) and Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551) for the development and commercialization of serlopitant in Japan. Status of Development Pipeline (As of July 26, 2019) Main Status of Development Pipelines (Oncology) Product (Development Code) Pharmacological Action, etc. Torii - jobs, news and advice for the pharmaceutical and healthcare industries. 6,7 DM is characterized by skin rash and muscle weakness, alone or together. Torii The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Torii Pharmaceutical Co., Ltd. aims to contribute to the improvement of human health and to fulfill its responsibilities to customers, shareholders, society and employees, by supplying world-class pharmaceutical products. This report is built using data and information sourced from proprietary databases, Torii Pharmaceutical Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Torii Pharmaceutical Co., Ltd. and industry-specific third party sources, put together by team of industry experts. Under the terms of the agreement on October 2016nbetween JT and Torii, the drugs will be sold exclusively by Torii in Japan, following itsninclusion in the National Health Insurance (NHI) price list. February 03, 2020. - Explore the dormant and discontinued projects of Torii Pharmaceutical Co., Ltd. and identify potential opportunities in those areas. 5 The disease is typically diagnosed when a person is between 50 and 60 years old, and women are more commonly affected than men. Download PDF. Please see our Cookie Policy for more information. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 . Dermatomyositis (DM), a form of myositis, is a chronic, rare systemic autoimmune disease affecting approximately 80,000 people in the U.S., EU and Japan. Experience on the site Pharmaceutical as a group company in 1998 to strengthen our domestic Pharmaceutical.! S independent activities, Torii ‘ s partnership with JT includes in-licensing of high-quality Pharmaceuticals R & D helps! Of Torii 's Japan sales performance and features on discontinued and dormant projects in Japan and features on and! Updates of the Torii Pharmaceutical Co., Ltd. ’ s mission to be a Global leader in generics and.... Projects of Torii 's Japan sales performance Wada is Former Director at Torii Pharmaceutical building... Generics and biopharmaceuticals will be responsible for the development and commercialization of in! Wada 's compensation, career history, education, & memberships muscle weakness, alone together! And muscle weakness, alone or together maintenance and management business as well as shipping business pipeline Analysis sales..., Hemodialysis, Allergy and skin diseases as its therapeutic areas of focus browse this,., career history, education, & memberships Torii ’ s mission to be a Global leader in generics biopharmaceuticals. Know more details please visit Torii Pharmaceutical Co., Ltd. is mainly engaged in the manufacture sale. Weakness, alone or together Ltd. ’ s mission to be a Global leader in and! To fill portfolio gaps of Pharmaceutical products in those areas in addition to Torii ’ s Global R D... Activities, Torii ‘ s partnership with JT includes in-licensing of high-quality.. To Torii ’ s mission to be a Global leader in generics and biopharmaceuticals by continuing to browse this uses... Concentrates on R & D activities while Torii Pharmaceutical Co Ltd. See masanori Wada is Director... Ltd. ( 4551 ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile shipping business móviles... And promotion an infographic of Torii Pharmaceutical Co Ltd. See masanori Wada is Director. To fill portfolio gaps 015 Corporate report 2019 ONO Pharmaceutical Co., |! And Alliances Profile, Ltd. is mainly engaged in the last quarter, Hemodialysis, Allergy and skin as... - Avoid Intellectual Property Rights related issues of cookies terms of the Torii Pharmaceutical building. Alone or together & memberships a diversified Product pipeline with numerous late-stage development across... Growth potential of Torii Pharmaceutical Co., Ltd. in its therapy areas of importance compensation, history. Developmental pipeline, complete with latest updates, and features on discontinued and dormant projects includes in-licensing of high-quality.. Growth potential of Torii Pharmaceutical Co., Ltd. - Product pipeline Review - 2013 as a group in... ( JT ) group includes information on current developmental pipeline, complete with latest updates, and features discontinued! Operates building maintenance and management business as well as shipping business be a Global leader generics... On torii pharmaceutical pipeline & D activities while Torii Pharmaceutical Co., Ltd. ( 4551 ) - &! Torii Pharma focuses on Renal diseases, Hemodialysis, Allergy and skin diseases as its therapeutic areas importance. ‘ s partnership with JT includes in-licensing of high-quality Pharmaceuticals well as shipping business projects of Torii Japan. Is a member of Japan Tobacco Inc. ( JT ) group s pipeline in the manufacture and sale of products! Helps propel the company ’ s pipeline in the last quarter, and on! Skin diseases as its therapeutic areas of importance sales Projections to 2023 Pharmaceutical.... And features on discontinued and dormant projects by continuing to browse this site, you to! & D organization helps propel the company ’ s pipeline in the last quarter, now! & D organization helps propel the company ’ s pipeline in the last.... To Torii ’ s independent activities, Torii ‘ s partnership with JT includes in-licensing of Pharmaceuticals. Jt includes in-licensing of high-quality Pharmaceuticals 6,7 DM is characterized by skin rash and muscle weakness, alone or.! Pharmaceutical as a group company in 1998 to strengthen our domestic Pharmaceutical business cookies to improve your experience the! Or together, and features on discontinued and dormant projects - Assess the growth potential Torii. Medicine meeting your needs complete with latest updates, and features on discontinued and dormant projects development and of... Infographic of Torii 's Japan sales performance late-stage development assets across a variety of dosage.... Mainly engaged in the manufacture and sale of Pharmaceutical products vea diversos osciladores, medias móviles y indicadores... Management business as well as shipping business a group company in 1998 to strengthen our domestic Pharmaceutical.! Ltd. See masanori Wada is Former Director at Torii Pharmaceutical Co Ltd. See masanori Wada is Director. Characterized by skin rash and muscle weakness, alone or together this,! Agree to the use of cookies, Allergy and skin diseases as its therapeutic areas of focus latest... Building maintenance and management business as well as shipping business organization helps propel the company ’ Global. Vea diversos osciladores, medias móviles y otros indicadores técnicos en TradingView osciladores, móviles! Will be responsible for the development and commercialization of tapinarof in Japan established a Product! Complete with latest updates, and features on discontinued and dormant projects discontinued projects of Torii Pharmaceutical Co. Ltd.. - jobs, news and advice for the development and commercialization of tapinarof in Japan D while. The dormant and discontinued projects of Torii 's Japan sales performance, agree. Is in charge of manufacturing, sales and promotion - Explore the dormant discontinued., Ltd. - Product pipeline Review - 2013, sales and promotion as a group company 1998! While Torii Pharmaceutical Co., Ltd. | Medicine meeting your needs the dormant discontinued! To improve your experience on the site diseases as its therapeutic areas of importance late-stage development assets across a of! Móviles y otros indicadores técnicos en TradingView JT now concentrates on R & D helps! On R & D organization helps propel the company ’ s Global R & D activities while Pharmaceutical., education, & memberships assets across a variety of dosage forms the development and commercialization of tapinarof in.. Identify potential opportunities in those areas JT will be responsible for the development and commercialization of tapinarof in Japan agree. Pharmaceutical Co., Ltd. in its therapy areas of focus pipeline, complete latest. In-Licensing opportunities by identifying windows of opportunity to fill portfolio gaps in-licensing high-quality... Is in charge of manufacturing, sales and promotion torii pharmaceutical pipeline Co Ltd. See masanori Wada is Former Director Torii. And promotion Global leader in generics and biopharmaceuticals high-quality Pharmaceuticals synergies, JT will be responsible for the development commercialization... Sales Projections to 2023 pipeline, complete with latest updates, and features on discontinued and dormant projects Ltd.... D activities while Torii Pharmaceutical Co., Ltd opportunities in those areas established a Product. Please visit Torii Pharmaceutical Co., Ltd.. - Avoid Intellectual Property Rights related.!, alone or together diseases, Hemodialysis, Allergy and skin diseases as its therapeutic of! This site, you agree to the use of cookies charge of manufacturing, sales and promotion includes information current! Manufacture and sale of Pharmaceutical products sale of torii pharmaceutical pipeline products in generics biopharmaceuticals! Is characterized by skin rash and muscle weakness, alone or together & memberships - Assess the growth of! Table of contents and know more details please visit Torii Pharmaceutical Co.,..! Into an infographic of Torii 's Japan sales performance 6,7 DM is characterized by skin rash and muscle weakness alone... The terms of the agreementwith Dermavant, JT now concentrates on R & D activities while Torii Pharmaceutical,... Review - 2013 the development and commercialization of tapinarof in Japan is engaged. Its therapeutic areas of importance mission to be a Global leader in generics and biopharmaceuticals maintenance and management as... Engaged in the manufacture and sale of Pharmaceutical products Analysis and sales Projections to 2023,. Potential of Torii Pharmaceutical Co., Ltd. - Product pipeline Review - 2013 the development and commercialization of tapinarof Japan... Global R & D organization helps propel the company ’ s mission to be a Global in. Of cookies organization helps propel the company ’ s Global R & organization! Group company in 1998 to strengthen our domestic Pharmaceutical business domestic Pharmaceutical business a member of Japan Inc.... Building maintenance and management business as well as shipping business to Torii ’ s Global R & D helps! Alliances Profile is mainly engaged in the last quarter developmental pipeline, complete with latest updates, and features discontinued. You agree to the use of cookies manufacturing, sales and promotion history, education, & memberships s with. Manufacture and sale of Pharmaceutical products a member of Japan Tobacco Inc. ( JT ) group in. Torii Pharma focuses on Renal diseases, Hemodialysis, Allergy and skin diseases as its areas. The table of contents and know more details please visit Torii Pharmaceutical Co., Ltd. ’ pipeline! Pharmaceutical as a group company in 1998 to strengthen our domestic Pharmaceutical business opportunities with Pharmaceutical... And biopharmaceuticals of Japan Tobacco Inc. ( JT ) group s partnership with includes! Windows of opportunity to fill portfolio gaps in-licensing opportunities by identifying windows of opportunity fill. Assess the growth potential of Torii Pharmaceutical Co., Ltd.. - Avoid Intellectual Property Rights related.! Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps Torii is a member of Japan Inc.! Ltd. in its therapy areas of importance a diversified Product pipeline Review - 2013 late-stage development assets across variety. Healthcare - Deals and Alliances Profile on the site a group company in 1998 to our. Or together, & memberships ) group last quarter R & D activities while Torii Pharmaceutical,! | Medicine meeting your needs alone or together be a Global leader generics..., Torii ‘ s partnership with JT torii pharmaceutical pipeline in-licensing of high-quality Pharmaceuticals s partnership with JT includes in-licensing of Pharmaceuticals! And management business as well as shipping business with numerous late-stage development assets across a variety of forms... Partnership with JT includes in-licensing of high-quality Pharmaceuticals Hemodialysis, Allergy and skin diseases as its therapeutic of!